Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

Xeris Biopharma Holdings, Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20
   8-K10-K10-K
Revenues:  
    Product revenue, net  109.3  
    Research and development  21.0  
Total revenues   [+]110.249.620.4
            Revenue growth  122.3%142.7% 
Cost of goods sold  43.613.39.3
Gross profit  66.636.311.1
            Gross margin  60.5%73.1%54.4%
Selling, general and administrative  137.7125.773.7
Research and development   25.220.9
EBITDA   [+]-71.1-113.3-82.1
            EBITDA margin  -64.5%-228.4%-401.7%
Depreciation   1.31.5
EBITA  -71.1-114.6-83.5
            EBITA margin  -64.5%-231.1%-408.8%
Amortization of intangibles  10.80.6 
EBIT   [+]-81.9-115.2-83.5
            EBIT margin  -74.3%-232.2%-408.8%
Interest expense, net   [+] 6.97.7
Other income (expense), net   [+]-14.1-0.70.1
Pre-tax income  -96.1-122.7-91.1
Income taxes  -1.40.00.1
            Tax rate  1.5%0.0% 
Net income  -94.7-122.7-91.3
            Net margin  -85.9%-247.5%-446.5%
   
Basic EPS   [+]($0.70)($1.55)($2.14)
Diluted EPS   [+]($0.70)($1.55)($2.14)
   
Shares outstanding (basic)   [+]135.679.042.6
Shares outstanding (diluted)   [+]135.679.042.6
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy